Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6 billion, a figure compiled in the Venture Monitor Report.
Elsewhere, the U.S. Justice Department unveiled a new task force that will go after the makers and distributors of opioid drugs, Celgene shocked investors with an unexpected setback, and a planned $4.3 billion merger… Read more »
UNDERWRITERS AND PARTNERS